Woodfield Distribution Llc

Woodfield Distribution, LLC, also known as WDSrx, is a privately held company specializing in integrated third-party logistics (3PL) services for the pharmaceutical industry. Established in 2010 and headquartered in Boca Raton, Florida, WDSrx offers a comprehensive suite of services, including warehousing, fulfillment, transportation management, and cold-chain capabilities. The company caters to a diverse clientele, encompassing pharmaceutical, supplement, animal health, specialty chemical, medical device, and personal care product manufacturers.

WDSrx operates multiple temperature-regulated facilities across the United States, with locations in Florida, New Jersey, Ohio, Texas, and Nevada. These facilities are licensed to meet current Good Manufacturing Practice (cGMP), Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), and other federal and state regulatory requirements, ensuring compliance for handling over-the-counter, prescription, and controlled substances.

In August 2023, WDSrx and its president, Adam Runsdorf, agreed to pay $2.475 million to resolve allegations of failing to properly account for controlled substances, highlighting the company's commitment to regulatory compliance.

WDSrx's distribution network comprises strategically located facilities across the United States, including Florida, New Jersey, Ohio, Texas, and Nevada. These facilities are equipped to handle a wide range of pharmaceutical products, including controlled substances, and are compliant with cGMP, FDA, DEA, and other regulatory standards.

The company's logistics capabilities encompass warehousing, fulfillment, transportation management, and cold-chain services, enabling efficient distribution of pharmaceutical products nationwide. WDSrx also manages e-commerce programs for direct-to-practitioner/patient and direct-to-consumer fulfillment, including platforms like Amazon FBA.

WDSrx functions as a third-party logistics (3PL) provider within the pharmaceutical supply chain, offering services such as warehousing, fulfillment, transportation management, and cold-chain capabilities. The company does not engage in the direct importation or distribution of pharmaceutical products but instead provides logistical support to manufacturers and distributors.

WDSrx's import activities from India are concentrated with a single supplier, RUBICON RESEARCH PRIVATE LIMITED, accounting for all 127 shipments valued at $5.8 million. This single-source dependency may pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume and frequency of shipments suggest a stable and long-term relationship between WDSrx and RUBICON RESEARCH PRIVATE LIMITED.

The resilience of WDSrx's Indian supply chain is contingent upon the reliability of RUBICON RESEARCH PRIVATE LIMITED. The lack of backup suppliers and the high concentration of imports from a single source indicate potential vulnerabilities. Additionally, the absence of information regarding the diversity of formulations imported and the exposure to specific shipping routes further underscores the need for a more diversified and resilient supply chain strategy.

The current sourcing pattern positions WDSrx as highly dependent on RUBICON RESEARCH PRIVATE LIMITED for its pharmaceutical imports from India. This dependency may limit the company's ability to negotiate favorable terms and could expose it to risks associated with supply chain disruptions. For Indian exporters, this presents an opportunity to become alternative suppliers to WDSrx, potentially reducing the company's reliance on a single source and enhancing supply chain resilience.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Enforcement Administration (DEA) regulations for controlled substances. The marketing authorization pathway for Indian generics involves obtaining FDA approval through the Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug.

Import licensing requirements for pharmaceutical products in the United States mandate that importers register with the FDA and, when applicable, the DEA for controlled substances. Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), are essential for ensuring product quality and safety. Importers must also obtain wholesale distribution authorization from state regulatory agencies to operate legally.

Pharmaceutical products imported into the United States must undergo batch testing to ensure compliance with FDA standards. Stability requirements are set to guarantee that products maintain their efficacy and safety throughout their shelf life. Labeling must include specific information, such as dosage instructions, active ingredients, and storage conditions, and must be in English. Serialization mandates require unique identifiers on packaging to enhance traceability and prevent counterfeit products.

Between 2024 and 2026, the FDA has implemented stricter regulations on the importation of pharmaceutical products, focusing on enhanced inspection protocols and increased scrutiny of manufacturing practices. These changes aim to bolster product safety and efficacy but may pose challenges for Indian exporters in meeting the updated compliance standards.

WDSrx's focus on cardiovascular products, including amiodarone, isosorbide, and carvedilol, aligns with the significant demand for these medications in the U.S. market. The company's import strategy is likely driven by the need to provide a consistent supply of these essential drugs, catering to the therapeutic needs of a substantial patient population.

WDSrx's sourcing strategy emphasizes the importation of generic pharmaceutical formulations from India, particularly in the cardiovascular category. The company's preference for specific formulations suggests a targeted approach to meet market demand and address therapeutic needs effectively.

Based on its product mix, WDSrx serves the wholesale distribution segment of the U.S. pharmaceutical market. By importing and distributing essential cardiovascular medications, the company plays a crucial role in ensuring the availability of these drugs to healthcare providers and patients nationwide.

There is a realistic opportunity for new Indian suppliers to engage with WDSrx, particularly in the cardiovascular product category. By offering high-quality generics that meet FDA standards, Indian exporters can fill gaps in WDSrx's current sourcing strategy, potentially reducing the company's reliance on a single supplier and enhancing supply chain resilience.

Indian exporters seeking to supply WDSrx must obtain FDA approval for their products, ensuring compliance with U.S. regulatory standards. Possessing GMP certificates from recognized authorities, such as EU GMP, WHO GMP, or PIC/S, is essential. Additionally, exporters must adhere to FDA labeling requirements and serialization mandates to facilitate market entry.

To establish a relationship with WDSrx, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with FDA and GMP standards. Participating in industry trade shows and networking events can also provide opportunities to engage with WDSrx representatives. Understanding the regulatory filing process and preparing for timely submissions will be crucial for successful collaboration.